1-(6-hydrazino-pyridazin-3-yl)-3,5-dimethyl-1H-pyrazol-4-ylamine | 77540-71-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-(6-hydrazino-pyridazin-3-yl)-3,5-dimethyl-1H-pyrazol-4-ylamine
• 英文别名: 3-hydrazino-6-(3,5-dimethyl-4-amino-1-pyrazolyl)-pyridazine；1-(6-Hydrazinylpyridazin-3-yl)-3,5-dimethylpyrazol-4-amine
• CAS: 77540-71-7
• 化学式: C₉H₁₃N₇
• 分子量: 219.249
• InChiKey: DOJSQOIVZKGPED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-(3,5-dimethyl-4-nitro-pyrazol-1-yl)-6-hydrazino-pyridazine 生成 1-(6-hydrazino-pyridazin-3-yl)-3,5-dimethyl-1H-pyrazol-4-ylamine
  参考文献：
  名称：

  SZILAGYI G.; KASZTREINER E.; TARDOS L.; JASZLITS L.; KOSA E.; CSEH G.; TO+, EUR. J. MED. CHEM.-CHIM. THER., 1979, 14, NO 5, 439-445

  摘要：

  DOI：

文献信息

• 3-(1-Pyrazolyl)-pyridazine derivatives and hypotensive compositions
  申请人：Richter Gedeon Vegyeszeti Gyar Rt.

  公开号：US04224325A1

  公开（公告）日：1980-09-23

  The invention relates to compounds of general formula ##STR1## wherein R.sup.1 stands for a hydrogen atom or a C.sub.1-6 alkyl-, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl or a phenyl group, R.sup.2 stands for a hydrogen, fluorine, chlorine or bromine atom or a C.sub.1-6 alkyl, a C.sub.2-4 hydroxyalkyl, a nitro or an --NR.sup.5 R.sup.6 group, wherein R.sup.5 and R.sup.6 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-4 alkyl or a C.sub.2-4 hydroxyalkyl group, R.sup.3 stands for a hydrogen atom or a C.sub.1-6 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl or a phenyl group, a chlorine atom or a hydroxyl, amino or methoxy group, R.sup.4 stands for a carbamoyl, a cyano or an --NR.sup.7 --NHR.sup.8 group, wherein R.sup.7 and R.sup.8 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-4 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.1-4 alkoxycarbonyl or an --NR.sup.9 R.sup.10 group, wherein R.sup.9 and R.sup.10 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-5 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl, a phenyl or a benzyl group, or --NR.sup.9 R.sup.10 may represent a morpholine, piperidine or piperazine ring, and their pharmaceutically acceptable acid-addition salts. Furthermore, the invention relates to a process for preparing these compounds. The novel compounds of general formula I have valuable pharmacological properties. Thus they show a considerable hypotensive effect and are capable to inhibit enzymes regulating the catabolism of prostaglandins.

  本发明涉及一般式##STR1##的化合物，其中R.sup.1代表氢原子或C.sub.1-6烷基，C.sub.2-4羟基烷基，C.sub.3-6环烷基或苯基，R.sup.2代表氢、氟、氯或溴原子或C.sub.1-6烷基，C.sub.2-4羟基烷基，硝基或--NR.sup.5 R.sup.6基团，其中R.sup.5和R.sup.6可能具有相同或不同的含义，分别代表氢原子或C.sub.1-4烷基或C.sub.2-4羟基烷基，R.sup.3代表氢原子或C.sub.1-6烷基，C.sub.2-4羟基烷基，C.sub.3-6环烷基或苯基，氯原子或羟基，氨基或甲氧基，R.sup.4代表氨基甲酰基，氰基或--NR.sup.7 --NHR.sup.8基团，其中R.sup.7和R.sup.8可能具有相同或不同的含义，分别代表氢原子或C.sub.1-4烷基，C.sub.2-4羟基烷基，C.sub.1-4烷氧羰基或--NR.sup.9 R.sup.10基团，其中R.sup.9和R.sup.10可能具有相同或不同的含义，分别代表氢原子或C.sub.1-5烷基，C.sub.2-4羟基烷基，C.sub.3-6环烷基，苯基或苄基，或--NR.sup.9 R.sup.10可以表示吗啡啶，哌啶或哌嗪环，并且它们的药学上可接受的酸盐。此外，本发明涉及一种制备这些化合物的方法。一般式I的新化合物具有有价值的药理特性。因此，它们表现出显著的降压作用，并能够抑制调节前列腺素分解代谢的酶。
• US4224325A
  申请人：——

  公开号：US4224325A

  公开（公告）日：1980-09-23